Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors
Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis ...
PipelineReview.com2h
Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors
Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated ...
Trump's Greenland dreams could ding huge North Carolina employer
Trump's threat of imposing a tariff on Denmark over desires to acquire Greenland has caught the attention of one of the ...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members ...
Nature1d
The weight-loss drugs being tested in 2025: will they beat Ozempic?
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
The Local1d
Danish weight-loss drugmaker Novo Nordisk posts huge profit jump
Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said on ...
LONDON MARKET MIDDAY: FTSE 100 edges up, gold gleams and GSK shines
The FTSE 100 index rose 12.01 points, 0.1%, at 8,582.78. The FTSE 250 declined 30.17 points, 0.2%, at 20,623.09. It traded off session lows, however. The AIM All-Share rose 0.72 of a point, 0.1%, at ...
Novo Nordisk Says It's Not Immune to Potential Trump Tariffs, but Business Is Well-Positioned
Wegovy maker Novo Nordisk is not immune to tariffs U.S. President Donald Trump is threatening to levy on the European Union, ...
Novo Nordisk sales beat estimates, but the story wasn't Ozempic
Novo Nordisk shares (DK:NOVO.B) (NVO) rallied 4% in early Copenhagen trade. Ozempic's 33.85 billion kroner of sales compared to analyst expectations of 33.34 billion kroner, and Wegovy's 19.87 billion ...
Novo Nordisk Defends Next-Gen Obesity Drug CagriSema, Gives Details of New Trial
LONDON/COPENHAGEN (Reuters) -Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday ...
Novo Nordisk: Q4 Earnings Snapshot
The Bagsvaerd, Denmark-based company said it had net income of 91 cents per share. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
Novo Nordisk A/S: Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024
At the Annual General Meeting on 27 March 2025, the Board of Directors will propose a final dividend of DKK 7.90 for 2024 per share. The expected total dividend for 2024 will increase 21% to DKK 11.40 ...